Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederinvestor.immunogen.com
ImmunoGen, Inc. News Releases
Get the latest updates from ImmunoGen, Inc. News Releases directly as they happen.
Follow now 63 followers
Latest posts
Last updated about 1 year ago
ImmunoGen Announces Pricing of Upsized Public Offering of Common Stock
about 2 years ago
WALTHAM, Mass. --(BUSINESS WIRE)--May 4, 2023-- ImmunoGen Inc. (Nasdaq: IMGN), a leader...
ImmunoGen Announces Proposed Public Offering of Common Stock
about 2 years ago
WALTHAM, Mass. --(BUSINESS WIRE)--May 3, 2023-- ImmunoGen Inc. (Nasdaq: IMGN), a leader...
ELAHERE® Demonstrates Overall Survival Benefit in the Phase 3 MIRASOL Trial in Patients with FRα-Positive Platinum-Resistant Ovarian Cancer
about 2 years ago
Results Show Statistically Significant Improvements in PFS, ORR, and OS Compared to...
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
about 2 years ago
WALTHAM, Mass. --(BUSINESS WIRE)--May 1, 2023-- ImmunoGen, Inc. , (Nasdaq: IMGN), a...
ImmunoGen Reports Recent Progress and First Quarter 2023 Financial Results
about 2 years ago
Strong Adoption of ELAHERE; Net Sales of $29.5 Million in First Full...
ImmunoGen Appoints Isabel Kalofonos as Senior Vice President and Chief Commercial Officer
about 2 years ago
WALTHAM, Mass. --(BUSINESS WIRE)--Apr. 24, 2023-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader...
ImmunoGen Announces Conference Call to Discuss Its First Quarter 2023 Operating Results
about 2 years ago
WALTHAM, Mass. --(BUSINESS WIRE)--Apr. 13, 2023-- ImmunoGen Inc. (Nasdaq: IMGN), a leader...
ImmunoGen Announces Non-Dilutive Term Loan Financing for Up to $175 Million with Pharmakon Advisors
about 2 years ago
ImmunoGen to Receive $75 Million Upon Execution of the Agreement; Eligible to...
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
about 2 years ago
WALTHAM, Mass. --(BUSINESS WIRE)--Apr. 3, 2023-- ImmunoGen, Inc. , (Nasdaq: IMGN), a...
ImmunoGen Presents Final Overall Survival and Additional Efficacy Data from the SORAYA Trial at SGO Annual Meeting
about 2 years ago
WALTHAM, Mass. --(BUSINESS WIRE)--Mar. 25, 2023-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader...
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
about 2 years ago
WALTHAM, Mass. --(BUSINESS WIRE)--Mar. 1, 2023-- ImmunoGen, Inc. , (Nasdaq: IMGN), a...
ImmunoGen Reports Recent Progress and 2022 Financial Results
about 2 years ago
Launched ELAHERE™ (mirvetuximab soravtansine-gynx), the First and Only ADC Approved for Platinum-Resistant...